Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Breast Diseases | 28 | 2021 | 436 | 2.050 |
Why?
|
Breast | 38 | 2021 | 1950 | 1.290 |
Why?
|
Breast Neoplasms | 121 | 2021 | 21074 | 1.230 |
Why?
|
Carcinoma, Ductal, Breast | 21 | 2017 | 1086 | 0.750 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 32 | 2014 | 921 | 0.710 |
Why?
|
Tomography, Optical Coherence | 9 | 2017 | 2877 | 0.630 |
Why?
|
Carcinoma in Situ | 15 | 2005 | 777 | 0.580 |
Why?
|
Mastectomy, Segmental | 19 | 2017 | 965 | 0.450 |
Why?
|
Pathology, Surgical | 3 | 2009 | 146 | 0.380 |
Why?
|
Cancer Care Facilities | 3 | 2020 | 427 | 0.370 |
Why?
|
Neoplasm Recurrence, Local | 40 | 2019 | 9378 | 0.350 |
Why?
|
Adenoma, Oxyphilic | 1 | 2011 | 150 | 0.340 |
Why?
|
Fibrocystic Breast Disease | 7 | 2013 | 101 | 0.330 |
Why?
|
Neoplasm Staging | 19 | 2017 | 11200 | 0.310 |
Why?
|
Bone Diseases, Infectious | 1 | 2007 | 16 | 0.280 |
Why?
|
Microscopy | 4 | 2014 | 900 | 0.280 |
Why?
|
Pathology, Clinical | 5 | 2010 | 374 | 0.250 |
Why?
|
Aspergillus fumigatus | 1 | 2007 | 158 | 0.250 |
Why?
|
Lymphatic Metastasis | 15 | 2017 | 2890 | 0.240 |
Why?
|
Aspergillosis | 1 | 2007 | 242 | 0.240 |
Why?
|
Microscopy, Confocal | 3 | 2017 | 1967 | 0.230 |
Why?
|
Accreditation | 2 | 2019 | 476 | 0.230 |
Why?
|
Mastectomy | 11 | 2019 | 1848 | 0.230 |
Why?
|
Thyroid Neoplasms | 5 | 2016 | 2354 | 0.230 |
Why?
|
Hearing Tests | 1 | 2005 | 123 | 0.230 |
Why?
|
Interferometry | 1 | 2004 | 101 | 0.220 |
Why?
|
Carcinoma | 10 | 2016 | 2313 | 0.220 |
Why?
|
Evoked Potentials, Auditory, Brain Stem | 1 | 2005 | 256 | 0.220 |
Why?
|
Problem Solving | 1 | 2006 | 442 | 0.210 |
Why?
|
Carcinoma, Lobular | 5 | 2017 | 471 | 0.200 |
Why?
|
Temporal Bone | 1 | 2007 | 683 | 0.200 |
Why?
|
Thyroid Gland | 2 | 2010 | 1168 | 0.190 |
Why?
|
Immunocompromised Host | 1 | 2007 | 865 | 0.190 |
Why?
|
Biopsy | 24 | 2015 | 6768 | 0.180 |
Why?
|
Practice Guidelines as Topic | 6 | 2019 | 7424 | 0.180 |
Why?
|
Neoplasms, Multiple Primary | 5 | 2000 | 590 | 0.170 |
Why?
|
Neonatal Screening | 1 | 2005 | 619 | 0.170 |
Why?
|
Female | 133 | 2021 | 396233 | 0.170 |
Why?
|
Biopsy, Needle | 5 | 2004 | 1613 | 0.160 |
Why?
|
Imaging, Three-Dimensional | 3 | 2017 | 4044 | 0.160 |
Why?
|
Precancerous Conditions | 6 | 2012 | 975 | 0.150 |
Why?
|
Microscopy, Ultraviolet | 1 | 2018 | 3 | 0.150 |
Why?
|
Parathyroid Neoplasms | 2 | 2011 | 244 | 0.150 |
Why?
|
Prognosis | 28 | 2020 | 29912 | 0.150 |
Why?
|
Combined Modality Therapy | 29 | 2005 | 8525 | 0.150 |
Why?
|
Middle Aged | 77 | 2021 | 223083 | 0.140 |
Why?
|
Hyperplasia | 12 | 2015 | 1142 | 0.140 |
Why?
|
Hearing Loss | 1 | 2005 | 785 | 0.140 |
Why?
|
Transillumination | 1 | 2016 | 20 | 0.140 |
Why?
|
Humans | 148 | 2021 | 766117 | 0.140 |
Why?
|
Alcohol Drinking | 5 | 2013 | 4044 | 0.140 |
Why?
|
Societies, Medical | 5 | 2009 | 3955 | 0.130 |
Why?
|
Hematoxylin | 1 | 2016 | 61 | 0.130 |
Why?
|
Eosine Yellowish-(YS) | 1 | 2016 | 70 | 0.130 |
Why?
|
Adult | 69 | 2021 | 223139 | 0.130 |
Why?
|
Carcinoma, Renal Cell | 1 | 2011 | 3186 | 0.130 |
Why?
|
Lymph Nodes | 5 | 2009 | 3456 | 0.130 |
Why?
|
Specimen Handling | 2 | 2009 | 704 | 0.130 |
Why?
|
Menarche | 2 | 2021 | 532 | 0.120 |
Why?
|
Microscopy, Fluorescence, Multiphoton | 1 | 2016 | 265 | 0.120 |
Why?
|
Kidney Neoplasms | 1 | 2011 | 4282 | 0.120 |
Why?
|
Image Enhancement | 3 | 2013 | 2857 | 0.110 |
Why?
|
Thyroid Diseases | 2 | 2010 | 385 | 0.110 |
Why?
|
Axilla | 8 | 2001 | 619 | 0.110 |
Why?
|
Image Interpretation, Computer-Assisted | 2 | 2016 | 3360 | 0.110 |
Why?
|
Diagnosis, Differential | 8 | 2016 | 12976 | 0.110 |
Why?
|
Insulin-Like Growth Factor I | 2 | 2012 | 1935 | 0.100 |
Why?
|
Insulin-Like Growth Factor Binding Protein 3 | 2 | 2012 | 416 | 0.100 |
Why?
|
Microscopy, Fluorescence | 2 | 2017 | 2627 | 0.100 |
Why?
|
Risk Factors | 32 | 2021 | 74857 | 0.100 |
Why?
|
Calcinosis | 5 | 2004 | 1475 | 0.100 |
Why?
|
Neoplasm Invasiveness | 10 | 2017 | 3602 | 0.100 |
Why?
|
Adenocarcinoma, Follicular | 1 | 2016 | 323 | 0.100 |
Why?
|
Aged | 40 | 2021 | 171219 | 0.100 |
Why?
|
Nonlinear Dynamics | 1 | 2014 | 490 | 0.100 |
Why?
|
Adenoma | 2 | 2016 | 2155 | 0.090 |
Why?
|
Lighting | 1 | 2013 | 211 | 0.090 |
Why?
|
Molecular Typing | 1 | 2011 | 115 | 0.090 |
Why?
|
Spinal Diseases | 1 | 2016 | 561 | 0.090 |
Why?
|
Technetium Tc 99m Sestamibi | 2 | 2002 | 185 | 0.090 |
Why?
|
Carcinoma, Papillary | 3 | 2016 | 786 | 0.090 |
Why?
|
Pattern Recognition, Automated | 1 | 2017 | 979 | 0.090 |
Why?
|
Image Processing, Computer-Assisted | 4 | 2018 | 8924 | 0.090 |
Why?
|
Hyperparathyroidism, Primary | 2 | 2011 | 164 | 0.090 |
Why?
|
Receptors, Progesterone | 6 | 2011 | 1152 | 0.090 |
Why?
|
Dietary Fiber | 3 | 2010 | 767 | 0.080 |
Why?
|
Diet | 4 | 2014 | 8087 | 0.080 |
Why?
|
Molecular Probe Techniques | 1 | 2010 | 111 | 0.080 |
Why?
|
Hyperparathyroidism | 1 | 2011 | 338 | 0.080 |
Why?
|
Lasers | 1 | 2013 | 951 | 0.080 |
Why?
|
Odds Ratio | 10 | 2015 | 9657 | 0.080 |
Why?
|
Tissue Array Analysis | 4 | 2011 | 544 | 0.080 |
Why?
|
Quality Indicators, Health Care | 1 | 2019 | 1804 | 0.080 |
Why?
|
Insulin-Like Growth Factor Binding Proteins | 1 | 2010 | 207 | 0.080 |
Why?
|
Parathyroidectomy | 1 | 2011 | 244 | 0.080 |
Why?
|
Histocytochemistry | 1 | 2010 | 695 | 0.080 |
Why?
|
Skin Neoplasms | 2 | 2018 | 5836 | 0.080 |
Why?
|
Receptor, IGF Type 1 | 1 | 2011 | 385 | 0.080 |
Why?
|
Mammography | 10 | 2004 | 2424 | 0.080 |
Why?
|
Adenocarcinoma | 4 | 2004 | 6363 | 0.080 |
Why?
|
Nuts | 1 | 2010 | 265 | 0.070 |
Why?
|
Ganglia, Sympathetic | 1 | 1987 | 65 | 0.070 |
Why?
|
Receptors, Estrogen | 7 | 2011 | 2242 | 0.070 |
Why?
|
Sensitivity and Specificity | 9 | 2017 | 14645 | 0.070 |
Why?
|
Parity | 3 | 2021 | 931 | 0.070 |
Why?
|
Proportional Hazards Models | 10 | 2014 | 12529 | 0.070 |
Why?
|
Patient Selection | 1 | 2019 | 4249 | 0.070 |
Why?
|
Case-Control Studies | 12 | 2021 | 22228 | 0.070 |
Why?
|
Guideline Adherence | 1 | 2016 | 2235 | 0.070 |
Why?
|
Gold | 1 | 2010 | 480 | 0.060 |
Why?
|
Cohort Studies | 14 | 2021 | 41684 | 0.060 |
Why?
|
Lymph Node Excision | 6 | 2004 | 1262 | 0.060 |
Why?
|
Manuals as Topic | 1 | 2006 | 99 | 0.060 |
Why?
|
Intestine, Large | 1 | 2005 | 69 | 0.060 |
Why?
|
Reproductive History | 2 | 2013 | 210 | 0.060 |
Why?
|
Disease-Free Survival | 4 | 2005 | 6840 | 0.060 |
Why?
|
Histological Techniques | 2 | 2018 | 193 | 0.060 |
Why?
|
Folic Acid | 1 | 2012 | 1337 | 0.060 |
Why?
|
Mississippi | 1 | 2005 | 93 | 0.060 |
Why?
|
Risk | 10 | 2012 | 9599 | 0.060 |
Why?
|
Quality Control | 2 | 2019 | 835 | 0.060 |
Why?
|
Neurosurgical Procedures | 1 | 2016 | 2078 | 0.060 |
Why?
|
Coloring Agents | 2 | 2017 | 563 | 0.060 |
Why?
|
Incidence | 11 | 2016 | 21513 | 0.060 |
Why?
|
Ultrasonography, Mammary | 2 | 2004 | 243 | 0.060 |
Why?
|
Stereotaxic Techniques | 2 | 2004 | 551 | 0.060 |
Why?
|
Nerve Growth Factors | 1 | 1987 | 564 | 0.060 |
Why?
|
Ear, Middle | 1 | 2007 | 341 | 0.060 |
Why?
|
Tomography, X-Ray Computed | 2 | 2007 | 20700 | 0.060 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2019 | 4054 | 0.060 |
Why?
|
Dietary Fats | 3 | 2014 | 2003 | 0.060 |
Why?
|
Parathyroid Hormone | 1 | 2011 | 1790 | 0.060 |
Why?
|
Aged, 80 and over | 12 | 2016 | 59515 | 0.060 |
Why?
|
Equipment Design | 3 | 2018 | 3489 | 0.060 |
Why?
|
Keratins | 4 | 2008 | 497 | 0.060 |
Why?
|
Gastrointestinal Tract | 1 | 2010 | 834 | 0.050 |
Why?
|
Microtomy | 2 | 1997 | 43 | 0.050 |
Why?
|
United States | 17 | 2017 | 72920 | 0.050 |
Why?
|
Necrosis | 2 | 2007 | 1614 | 0.050 |
Why?
|
Retrospective Studies | 21 | 2020 | 81565 | 0.050 |
Why?
|
Sampling Studies | 1 | 2004 | 613 | 0.050 |
Why?
|
Fibroadenoma | 1 | 2002 | 40 | 0.050 |
Why?
|
Menopause | 4 | 2021 | 1659 | 0.050 |
Why?
|
Prospective Studies | 18 | 2015 | 54812 | 0.050 |
Why?
|
Fatal Outcome | 1 | 2007 | 1836 | 0.050 |
Why?
|
Immunohistochemistry | 4 | 2018 | 11035 | 0.050 |
Why?
|
Neoplasm Metastasis | 6 | 2017 | 4887 | 0.050 |
Why?
|
Calcium | 2 | 2012 | 5770 | 0.050 |
Why?
|
Medical Records | 2 | 2009 | 1408 | 0.050 |
Why?
|
Neoplasm, Residual | 2 | 1997 | 1009 | 0.050 |
Why?
|
Chemotherapy, Adjuvant | 4 | 2011 | 3546 | 0.050 |
Why?
|
Clinical Protocols | 4 | 2009 | 1437 | 0.050 |
Why?
|
Radiopharmaceuticals | 2 | 2002 | 2702 | 0.050 |
Why?
|
Sentinel Lymph Node Biopsy | 1 | 2006 | 733 | 0.050 |
Why?
|
Physicians | 1 | 2019 | 4591 | 0.050 |
Why?
|
Keratin-5 | 2 | 2011 | 43 | 0.050 |
Why?
|
Follow-Up Studies | 21 | 2020 | 39243 | 0.050 |
Why?
|
Vascular Endothelial Growth Factor A | 2 | 2011 | 3501 | 0.050 |
Why?
|
Specialty Boards | 1 | 2003 | 235 | 0.050 |
Why?
|
Estrogen Replacement Therapy | 2 | 2013 | 1206 | 0.050 |
Why?
|
Predictive Value of Tests | 8 | 2021 | 15403 | 0.040 |
Why?
|
Cell Transformation, Neoplastic | 4 | 1999 | 2838 | 0.040 |
Why?
|
Reproducibility of Results | 5 | 2017 | 20137 | 0.040 |
Why?
|
Feasibility Studies | 2 | 2010 | 5300 | 0.040 |
Why?
|
Autopsy | 1 | 2004 | 1011 | 0.040 |
Why?
|
Observer Variation | 4 | 2004 | 2611 | 0.040 |
Why?
|
Lymphatic Irradiation | 1 | 2000 | 110 | 0.040 |
Why?
|
Diagnostic Errors | 1 | 2007 | 1276 | 0.040 |
Why?
|
Pathology | 1 | 2003 | 270 | 0.040 |
Why?
|
Algorithms | 2 | 2017 | 14066 | 0.040 |
Why?
|
Intestine, Small | 1 | 2005 | 1216 | 0.040 |
Why?
|
Sarcoma, Kaposi | 1 | 2002 | 376 | 0.040 |
Why?
|
Actuarial Analysis | 4 | 1994 | 370 | 0.040 |
Why?
|
Bone Marrow Transplantation | 1 | 2007 | 2729 | 0.040 |
Why?
|
Elasticity | 1 | 2021 | 652 | 0.040 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 2002 | 663 | 0.040 |
Why?
|
Hearing Loss, Sensorineural | 1 | 2005 | 782 | 0.040 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 4565 | 0.040 |
Why?
|
Vitamin D | 1 | 2012 | 3272 | 0.040 |
Why?
|
Nanoparticles | 1 | 2010 | 1966 | 0.040 |
Why?
|
Acridine Orange | 1 | 2017 | 28 | 0.040 |
Why?
|
Light | 1 | 2004 | 1358 | 0.040 |
Why?
|
Gene Expression | 1 | 2011 | 7582 | 0.040 |
Why?
|
Body Size | 1 | 2021 | 460 | 0.040 |
Why?
|
Mammary Neoplasms, Experimental | 2 | 1996 | 496 | 0.040 |
Why?
|
Adolescent | 11 | 2016 | 88819 | 0.040 |
Why?
|
Risk Assessment | 5 | 2021 | 24276 | 0.040 |
Why?
|
Rhodamines | 1 | 2017 | 178 | 0.040 |
Why?
|
Radiotherapy Dosage | 3 | 2004 | 2863 | 0.030 |
Why?
|
Analysis of Variance | 3 | 2021 | 6208 | 0.030 |
Why?
|
Nurses | 4 | 2013 | 2503 | 0.030 |
Why?
|
Contrast Media | 1 | 2010 | 5330 | 0.030 |
Why?
|
Internship and Residency | 2 | 2010 | 5946 | 0.030 |
Why?
|
Treatment Failure | 2 | 2000 | 2653 | 0.030 |
Why?
|
Intraoperative Period | 1 | 2017 | 511 | 0.030 |
Why?
|
Gene Expression Profiling | 2 | 2011 | 9527 | 0.030 |
Why?
|
Treatment Outcome | 12 | 2011 | 65219 | 0.030 |
Why?
|
Gelsolin | 1 | 1996 | 189 | 0.030 |
Why?
|
Receptor, erbB-2 | 3 | 2011 | 2593 | 0.030 |
Why?
|
Surgery, Computer-Assisted | 1 | 2004 | 996 | 0.030 |
Why?
|
Vitamins | 1 | 2004 | 1631 | 0.030 |
Why?
|
Adiposity | 1 | 2005 | 1892 | 0.030 |
Why?
|
HIV Infections | 1 | 2002 | 17535 | 0.030 |
Why?
|
Neoplasms | 3 | 2005 | 22344 | 0.030 |
Why?
|
Palpation | 2 | 2004 | 166 | 0.030 |
Why?
|
Regression Analysis | 5 | 2010 | 6324 | 0.030 |
Why?
|
Carcinoma, Medullary | 2 | 2007 | 115 | 0.030 |
Why?
|
Adolescent Behavior | 1 | 2003 | 1184 | 0.030 |
Why?
|
Premenopause | 2 | 2012 | 1039 | 0.030 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2002 | 1374 | 0.030 |
Why?
|
Retroelements | 1 | 1996 | 163 | 0.030 |
Why?
|
Genetic Variation | 1 | 2010 | 6612 | 0.030 |
Why?
|
Exercise | 1 | 2011 | 5939 | 0.030 |
Why?
|
Academic Medical Centers | 1 | 2005 | 2782 | 0.030 |
Why?
|
Genomics | 1 | 2010 | 5926 | 0.030 |
Why?
|
Survival Rate | 4 | 2010 | 12827 | 0.030 |
Why?
|
Receptors, Growth Factor | 1 | 1995 | 324 | 0.030 |
Why?
|
Young Adult | 4 | 2016 | 59868 | 0.030 |
Why?
|
Time Factors | 10 | 2013 | 40108 | 0.030 |
Why?
|
Carbon | 1 | 1997 | 673 | 0.030 |
Why?
|
Software | 1 | 2007 | 4463 | 0.030 |
Why?
|
Cicatrix | 1 | 1999 | 796 | 0.030 |
Why?
|
Salvage Therapy | 2 | 2005 | 1273 | 0.030 |
Why?
|
Estrogens | 1 | 1999 | 1528 | 0.030 |
Why?
|
Adenocarcinoma, Mucinous | 3 | 2004 | 521 | 0.030 |
Why?
|
Endothelial Growth Factors | 1 | 1995 | 671 | 0.020 |
Why?
|
Cross-Sectional Studies | 3 | 2020 | 26290 | 0.020 |
Why?
|
Keratin-6 | 1 | 2011 | 15 | 0.020 |
Why?
|
Lymphokines | 1 | 1995 | 905 | 0.020 |
Why?
|
Micronutrients | 1 | 2014 | 390 | 0.020 |
Why?
|
Cytoplasm | 2 | 2011 | 1498 | 0.020 |
Why?
|
Dietary Supplements | 1 | 2004 | 3427 | 0.020 |
Why?
|
Multivariate Analysis | 4 | 2012 | 12061 | 0.020 |
Why?
|
Equipment Failure Analysis | 1 | 2013 | 831 | 0.020 |
Why?
|
Logistic Models | 4 | 2010 | 13273 | 0.020 |
Why?
|
Nutritional Requirements | 1 | 2012 | 276 | 0.020 |
Why?
|
Subrenal Capsule Assay | 1 | 1990 | 27 | 0.020 |
Why?
|
Body Mass Index | 3 | 2021 | 13046 | 0.020 |
Why?
|
Immunoenzyme Techniques | 2 | 2010 | 1695 | 0.020 |
Why?
|
Hybrid Cells | 1 | 1990 | 420 | 0.020 |
Why?
|
Diagnostic Imaging | 1 | 2004 | 3530 | 0.020 |
Why?
|
Adipose Tissue | 1 | 2002 | 3315 | 0.020 |
Why?
|
Fluorescent Dyes | 1 | 2017 | 1928 | 0.020 |
Why?
|
Cell Fusion | 1 | 1990 | 294 | 0.020 |
Why?
|
ROC Curve | 1 | 2017 | 3614 | 0.020 |
Why?
|
Women's Health | 3 | 2004 | 2081 | 0.020 |
Why?
|
Epithelial Cells | 2 | 1998 | 3684 | 0.020 |
Why?
|
Neurons | 1 | 1987 | 9521 | 0.020 |
Why?
|
Double-Blind Method | 2 | 1992 | 12426 | 0.020 |
Why?
|
Adrenal Medulla | 1 | 1987 | 56 | 0.020 |
Why?
|
Microscopy, Electron, Scanning | 2 | 1987 | 938 | 0.020 |
Why?
|
Age Distribution | 1 | 2013 | 2865 | 0.020 |
Why?
|
Age Factors | 6 | 2005 | 18386 | 0.020 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 1995 | 1621 | 0.020 |
Why?
|
Radionuclide Imaging | 2 | 2002 | 1985 | 0.020 |
Why?
|
Family Health | 2 | 2006 | 1253 | 0.020 |
Why?
|
Vasoactive Intestinal Peptide | 1 | 1987 | 179 | 0.020 |
Why?
|
S100 Proteins | 1 | 1987 | 214 | 0.020 |
Why?
|
Chromogranins | 1 | 1987 | 159 | 0.020 |
Why?
|
Radiotherapy, Adjuvant | 2 | 2004 | 1777 | 0.020 |
Why?
|
Neoplasms, Second Primary | 1 | 1993 | 1056 | 0.020 |
Why?
|
Lipoma | 1 | 1987 | 294 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 1 | 2006 | 18076 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2005 | 26381 | 0.010 |
Why?
|
Postmenopause | 1 | 2013 | 2517 | 0.010 |
Why?
|
Epithelium | 3 | 1999 | 1604 | 0.010 |
Why?
|
Male | 7 | 2020 | 363935 | 0.010 |
Why?
|
Neoplasm Proteins | 1 | 1996 | 3594 | 0.010 |
Why?
|
Haplotypes | 1 | 2010 | 2726 | 0.010 |
Why?
|
Hot Temperature | 1 | 2010 | 1440 | 0.010 |
Why?
|
Cell Membrane | 2 | 2011 | 3635 | 0.010 |
Why?
|
Boston | 1 | 2016 | 9335 | 0.010 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2011 | 1535 | 0.010 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2010 | 958 | 0.010 |
Why?
|
Transfection | 1 | 1990 | 5739 | 0.010 |
Why?
|
Biopsy, Fine-Needle | 1 | 2007 | 1131 | 0.010 |
Why?
|
Adrenal Gland Neoplasms | 1 | 1987 | 731 | 0.010 |
Why?
|
Health Surveys | 1 | 2012 | 4058 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 1993 | 11859 | 0.010 |
Why?
|
False Positive Reactions | 1 | 2004 | 956 | 0.010 |
Why?
|
Thyroidectomy | 1 | 2007 | 912 | 0.010 |
Why?
|
Radiotherapy | 4 | 1990 | 1491 | 0.010 |
Why?
|
Genes, erbB | 1 | 2000 | 5 | 0.010 |
Why?
|
Diet Surveys | 1 | 2004 | 1159 | 0.010 |
Why?
|
Meningioma | 1 | 1989 | 1221 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2012 | 10737 | 0.010 |
Why?
|
Meningeal Neoplasms | 1 | 1989 | 1252 | 0.010 |
Why?
|
Ploidies | 1 | 2000 | 287 | 0.010 |
Why?
|
Certification | 1 | 2003 | 420 | 0.010 |
Why?
|
Cell Nucleus | 2 | 2005 | 2864 | 0.010 |
Why?
|
Survival Analysis | 3 | 2000 | 10087 | 0.010 |
Why?
|
Child | 1 | 2007 | 80573 | 0.010 |
Why?
|
DNA-Binding Proteins | 1 | 1996 | 9601 | 0.010 |
Why?
|
Pregnancy | 2 | 2013 | 30233 | 0.010 |
Why?
|
Vegetables | 1 | 2003 | 1200 | 0.010 |
Why?
|
Genes, p53 | 1 | 2000 | 711 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 1996 | 11906 | 0.010 |
Why?
|
Rats | 2 | 1996 | 23717 | 0.010 |
Why?
|
Radiation Injuries | 1 | 1984 | 1181 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2004 | 36548 | 0.010 |
Why?
|
Curriculum | 1 | 2010 | 3784 | 0.010 |
Why?
|
Cell Division | 2 | 1997 | 4466 | 0.010 |
Why?
|
Phospholipase D | 1 | 1996 | 71 | 0.010 |
Why?
|
Teratocarcinoma | 1 | 1996 | 16 | 0.010 |
Why?
|
Antioxidants | 1 | 2004 | 1671 | 0.010 |
Why?
|
Tumor Cells, Cultured | 2 | 1996 | 6102 | 0.010 |
Why?
|
Chi-Square Distribution | 1 | 2002 | 3432 | 0.010 |
Why?
|
Mice, Inbred C3H | 1 | 1996 | 915 | 0.010 |
Why?
|
Blotting, Western | 2 | 1996 | 5020 | 0.010 |
Why?
|
Mitosis | 1 | 2000 | 1175 | 0.010 |
Why?
|
Mammary Glands, Animal | 1 | 1996 | 272 | 0.010 |
Why?
|
DNA, Neoplasm | 1 | 2000 | 1739 | 0.010 |
Why?
|
Nerve Tissue Proteins | 1 | 1987 | 4399 | 0.010 |
Why?
|
Antibodies, Monoclonal | 2 | 1988 | 9237 | 0.010 |
Why?
|
Clinical Competence | 1 | 2010 | 4859 | 0.010 |
Why?
|
World Health Organization | 1 | 2000 | 1326 | 0.010 |
Why?
|
Stromal Cells | 1 | 1999 | 1332 | 0.010 |
Why?
|
Cells, Cultured | 2 | 1987 | 18967 | 0.010 |
Why?
|
Health Care Surveys | 1 | 2000 | 2426 | 0.010 |
Why?
|
Vascular Endothelial Growth Factors | 1 | 1995 | 748 | 0.010 |
Why?
|
Mutagenesis, Insertional | 1 | 1996 | 663 | 0.010 |
Why?
|
Confidence Intervals | 1 | 1997 | 2915 | 0.010 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 1 | 1995 | 658 | 0.010 |
Why?
|
Family | 1 | 2002 | 3208 | 0.010 |
Why?
|
Prevalence | 1 | 2008 | 15827 | 0.010 |
Why?
|
Receptors, Cell Surface | 1 | 2000 | 2815 | 0.010 |
Why?
|
In Situ Hybridization | 1 | 1995 | 1885 | 0.010 |
Why?
|
RNA, Messenger | 2 | 1996 | 12775 | 0.010 |
Why?
|
Phenotype | 1 | 2008 | 16716 | 0.010 |
Why?
|
Radioisotope Teletherapy | 1 | 1989 | 15 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2010 | 16040 | 0.010 |
Why?
|
Actins | 1 | 1996 | 2061 | 0.000 |
Why?
|
Esthetics | 1 | 1991 | 327 | 0.000 |
Why?
|
Adenofibroma | 1 | 1987 | 25 | 0.000 |
Why?
|
Mice, Inbred BALB C | 1 | 1996 | 6215 | 0.000 |
Why?
|
Brain Neoplasms | 1 | 1989 | 9065 | 0.000 |
Why?
|
Ganglioneuroma | 1 | 1987 | 53 | 0.000 |
Why?
|
Evaluation Studies as Topic | 1 | 1989 | 1607 | 0.000 |
Why?
|
Molecular Weight | 1 | 1988 | 2161 | 0.000 |
Why?
|
Smoking | 1 | 2002 | 9082 | 0.000 |
Why?
|
Rats, Sprague-Dawley | 1 | 1996 | 8113 | 0.000 |
Why?
|
Pheochromocytoma | 1 | 1987 | 326 | 0.000 |
Why?
|
Postoperative Period | 1 | 1990 | 1820 | 0.000 |
Why?
|
Animals | 4 | 1996 | 168800 | 0.000 |
Why?
|
Fluorouracil | 1 | 1989 | 1648 | 0.000 |
Why?
|
Mitotic Index | 1 | 1984 | 160 | 0.000 |
Why?
|
Cyclophosphamide | 1 | 1989 | 2232 | 0.000 |
Why?
|
Mice, Nude | 1 | 1990 | 3610 | 0.000 |
Why?
|
Methotrexate | 1 | 1989 | 1719 | 0.000 |
Why?
|
Europe | 1 | 1989 | 3430 | 0.000 |
Why?
|
Doxorubicin | 1 | 1989 | 2226 | 0.000 |
Why?
|
Longitudinal Studies | 1 | 1999 | 14747 | 0.000 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 1983 | 870 | 0.000 |
Why?
|
Clinical Trials as Topic | 2 | 1987 | 8038 | 0.000 |
Why?
|
Hemadsorption | 1 | 1980 | 7 | 0.000 |
Why?
|
Receptors, Concanavalin A | 1 | 1980 | 11 | 0.000 |
Why?
|
Cytochalasin B | 1 | 1980 | 74 | 0.000 |
Why?
|
Concanavalin A | 1 | 1980 | 189 | 0.000 |
Why?
|
Brachytherapy | 1 | 1988 | 1218 | 0.000 |
Why?
|
Hyaluronoglucosaminidase | 1 | 1980 | 138 | 0.000 |
Why?
|
Microbial Collagenase | 1 | 1980 | 112 | 0.000 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 1996 | 8612 | 0.000 |
Why?
|
Trypsin | 1 | 1980 | 487 | 0.000 |
Why?
|
Mice | 3 | 1996 | 81839 | 0.000 |
Why?
|
Colchicine | 1 | 1980 | 256 | 0.000 |
Why?
|
Disease Progression | 1 | 1995 | 13616 | 0.000 |
Why?
|
Surface Properties | 1 | 1980 | 1152 | 0.000 |
Why?
|
Bone Neoplasms | 1 | 1989 | 2559 | 0.000 |
Why?
|
Reoperation | 1 | 1987 | 4309 | 0.000 |
Why?
|
Patient Care Team | 1 | 1987 | 2517 | 0.000 |
Why?
|
Radiography | 1 | 1987 | 6943 | 0.000 |
Why?
|
Signal Transduction | 1 | 1996 | 23605 | 0.000 |
Why?
|
Antineoplastic Agents | 1 | 1986 | 13635 | 0.000 |
Why?
|